TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31726714

Group type: EXPERIMENTAL
Intervention: Winter ice-cream intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Chickpeas intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Not industrial aged-cheeses type
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Rabbit meat
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Industrial type aged cheeses
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Milk-based desserts (no winter ice cream)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fats
Number of subjects: 136
Study: 26711194

Group type: EXPERIMENTAL
Intervention: Head-down-tilt sleeping hypokinetic subjects (HDTSHS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Head-down-tilt sleeping control subjects (HDTSCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypokinetic subjects (HKS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control subjects (ACS)
Number of subjects: 40
Study: 26004031

Group type: EXPERIMENTAL
Intervention: 6-week program of enhanced physiotherapy and structured exercise (PEPSE) and essential amino acid supplement drink (glutamine and essential amino acid mixture [GEAA])
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: GEAA supplement with PEPSE
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control supplement/PEPSE
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: GEAA supplement/PEPSE
Number of subjects: 93
Study: 24229738

Group type: EXPERIMENTAL
Intervention: GeneSight pharmacogenomic-informed treatment (n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=25)
Number of subjects: 51
Study: 21714710

Group type: EXPERIMENTAL
Intervention: Generic SFG (Nulecit)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Branded SFG (Ferrlecit)
Number of subjects: 240
Study: 19046471

Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 16913263

Group type: EXPERIMENTAL
Intervention: R112
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study: 15000796

Group type: EXPERIMENTAL
Intervention: Palliative care integration with case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 11323501

Group type: EXPERIMENTAL
Intervention: c-erbB-2 expression
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: p53 expression
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Coexpression of c-erbB-2 and p53
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: T stage
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Nodal status
Number of subjects: 311
Study: 9416313

Group type: EXPERIMENTAL
Intervention: Lactate levels in peritumoral edema
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lactate levels in peritumoral edematous tissue
Number of subjects: 18
Study: 8487513

Group type: EXPERIMENTAL
Intervention: Drug and alcohol abuse prenatal care health education program
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study: 3324648

Group type: EXPERIMENTAL
Intervention: Citalopram (40 or 60 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Maprotiline (75 or 150 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 96

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 96
Study: 29273390

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 643

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 643
Study: 27064499

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 28

Group type: COMPARATOR
Intervention: DAPT alone (Control)
Number of subjects: 28
Study: 24679203

Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc System
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ACCEL system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 23747582

Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 71
Study: 20978447

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg bevacizumab
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 15 mg/kg bevacizumab
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 19055885

Group type: EXPERIMENTAL
Intervention: Conventional resin sealant
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (RMGI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (RMGI)
Number of subjects: 45
Study: 16322492

Group type: EXPERIMENTAL
Intervention: FNS‐IM (Functional Neuromuscular Stimulation using intramuscular electrodes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No‐FNS (No Functional Neuromuscular Stimulation)
Number of subjects: 32
Study: 14653434

Group type: EXPERIMENTAL
Intervention: Subcortical hyperintensity (SH) volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-brain volume (WBV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcortical hyperintensity (SH) volume after 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-brain volume (WBV) after 12 months
Number of subjects: 0
Study: 11286465

Group type: EXPERIMENTAL
Intervention: Megestrol 160 mg day(-1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 45
Study: 9240185

Group type: EXPERIMENTAL
Intervention: tamsulosin (0.2 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: allylestrenol (50 mg/day)
Number of subjects: 128
Study: 8214993

Group type: EXPERIMENTAL
Intervention: Lovastatin, 80 mg/day
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 3312862

Group type: EXPERIMENTAL
Intervention: Sunscreen cream (Pabafil SPF 10, with absorption range from 290 to 360 nm)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sunscreen cream
Number of subjects: 65
Study: 30923309

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 57
Study: 28281051

Group type: EXPERIMENTAL
Intervention: OSG + E (therapist-led, 10-week synchronous online intervention)
Number of subjects: 105

Group type: COMPARATOR
Intervention: E (self-help workbook)
Number of subjects: 105
Study: 24738609

Group type: EXPERIMENTAL
Intervention: Tapentadol PR (500 mg/day)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Tapentadol PR (300 mg/day) / Pregabalin (300 mg/day)
Number of subjects: 288
Study: 23672789

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2‐4 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Atorvastatin 10‐20mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Neither statin
Number of subjects: 129
Study: 21732669

Group type: EXPERIMENTAL
Intervention: Selenium-fortified broccoli (200 g daily for 4 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Regular broccoli (200 g daily for 4 weeks)
Number of subjects: 76
Study: 19185634

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (guideline dissemination via a continuing medical education session, academic detailing sessions, audit and feedback, automated blood pressure machines)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Attention control (targeted at a different guideline)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 61
Study: 16874778

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and every 6 weeks thereafter through week 24
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12631532

Group type: EXPERIMENTAL
Intervention: Patients with MTL lesions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 18
Study: 10837017

Group type: EXPERIMENTAL
Intervention: Isoflavonoids (genistein at 12.5-100 microM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enterolactone (100 microM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dihydrogenistein (100 microM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formononetin (100 microM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rye crispbread (76.5 g/day for 2 weeks)
Number of subjects: 12
Study: 8780091

Group type: EXPERIMENTAL
Intervention: Standard carbidopa/levodopa (Std‐L)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sustained-release carbidopa/levodopa (L‐CR)
Number of subjects: 15
Study: 1473430

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times daily with meals and at bedtime)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 6233731

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30888118

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m2 q3 months for 2 years)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 263
Study: 29154407

Group type: COMPARATOR
Intervention: Muscle strength group (n=15)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Perturbation-based group (n=16)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 47
Study: 26840703

Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISWI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intracutaneous isotonic saline injections (placebo treatment)
Number of subjects: 68
Study: 25367539

Group type: EXPERIMENTAL
Intervention: Reflecting on experiences of unconditional regard (n = 91)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Reflecting on experiences of conditional regard (n = 80)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Reflecting on other social experiences (n = 76)
Number of subjects: 247
Study: 22742888

Group type: EXPERIMENTAL
Intervention: Vision restoration therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saccadic training (control intervention)
Number of subjects: 80
Study: 20955629

Group type: COMPARATOR
Intervention: Condom-only control group
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Diaphragm group
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 801
Study: 17658567

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg for age > or =12 years, 200mg for age 4-11 years, 100mg for age 1-3 years)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg for adults with hepatic amoebiasis)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500mg)
Number of subjects: 81
Study: 16362456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CaCO3)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CaCO3) + 1,200 IU of cholecalciferol
Number of subjects: 53
Study: 12558088

Group type: EXPERIMENTAL
Intervention: Preoperative oral slow-release tramadol
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 10217370

Group type: EXPERIMENTAL
Intervention: 2.4 g aged garlic extract (AGE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 g DL‐alpha‐tocopherol acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 g raw garlic
Number of subjects: 0
Study: 9505452

Group type: EXPERIMENTAL
Intervention: New antenatal care programme
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard antenatal care programme (Control)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 265
Study: 2202248

Group type: EXPERIMENTAL
Intervention: 0.5 ppm ozone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 12
Study: 7038316

Group type: EXPERIMENTAL
Intervention: Low-dose verapamil (0.075 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Standard-dose verapamil (0.15 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Verapamil (low-dose and standard-dose)
Number of subjects: 28
Study: 31630358

Group type: EXPERIMENTAL
Intervention: TAT-SOD (0.2 mL of 3000 U/mL TAT-SOD cream) applied topically at acupoint ST 36 once a day for 15 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo cream applied topically at acupoint ST 36 once a day for 15 days
Number of subjects: 16
Study: 30818837

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Expressive writing (EW)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 160
Study: 27625122

Group type: EXPERIMENTAL
Intervention: Core stabilization training in addition to traditional rehabilitation (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional rehabilitation (n=13)
Number of subjects: 25
Study: 27077745

Group type: EXPERIMENTAL
Intervention: Enhanced appointment reminders (dated appointment card plus SMS and phone call reminders, or in-person reminders)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard appointment reminders (dated appointment card)
Number of subjects: 410
Study: 24411428

Group type: EXPERIMENTAL
Intervention: FLS simulator
Number of subjects: 26

Group type: COMPARATOR
Intervention: LapSim simulator
Number of subjects: 26
Study: 22541893

Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD) 30 mg/m² IV followed by a 3-h infusion of trabectedin 1.1 mg/m² every 3 weeks
Number of subjects: 672

Group type: COMPARATOR
Intervention: PLD 50 mg/m² every 4 weeks
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Trabectedin plus PLD in patients with PFI of 6-12 months
Number of subjects: 672
Study: 20430851

Group type: EXPERIMENTAL
Intervention: MRS combined with DWI
Number of subjects: 45
Study: 18018769

Group type: EXPERIMENTAL
Intervention: 16 SU inactivated SARS-CoV vaccine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 32 SU inactivated SARS-CoV vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 36
Study: 16081875

Group type: EXPERIMENTAL
Intervention: Inspiratory threshold load of 15 cmH2O
Number of subjects: 14
Study: 12150647

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (CBT)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both CBT and IPT
Number of subjects: 162
Study: 9920144

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment (gemfibrozil + lovastatin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gemfibrozil alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 30
Study: 7501353

Group type: EXPERIMENTAL
Intervention: Antenatal vitamin K and phenobarbital therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2253912

Group type: EXPERIMENTAL
Intervention: Olsalazine (1 g twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pentasa (750 + 500 + 750 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Salofalk (750 + 500 + 750 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 14
Study: 6986082

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 11894

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11894
Study: 30683195

Group type: EXPERIMENTAL
Intervention: Best Endovascular Therapy
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Best Surgical Therapy
Number of subjects: 2100
Study: 28902580

Group type: EXPERIMENTAL
Intervention: PFO closure plus antiplatelet therapy
Number of subjects: 664

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664
Study: 26212317

Group type: EXPERIMENTAL
Intervention: Automated reminder messages
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study: 23895150

Group type: EXPERIMENTAL
Intervention: Stir-fried white pepper
Number of subjects: 174

Group type: COMPARATOR
Intervention: Montmorillonite powder
Number of subjects: 174
Study: 21309696

Group type: EXPERIMENTAL
Intervention: Donepezil (5 and 10 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19848610

Group type: EXPERIMENTAL
Intervention: Intermittent preventive sulfadoxine-pyrimethamine treatment
Number of subjects: 0
Study: 17447832

Group type: COMPARATOR
Intervention: Pramipexole 0.125, 0.25, 0.50 or 0.75 mg once daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pramipexole at a median dosage of 0.35 mg/day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pramipexole for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pramipexole after 6 months' therapy
Number of subjects: 0
Study: 15077870

Group type: EXPERIMENTAL
Intervention: Polysulfone high-flux hemodialysis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Polysulfone low-flux hemodialysis
Number of subjects: 29
Study: 11487163

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcium oxide
Number of subjects: 36
Study: 10093521

Group type: EXPERIMENTAL
Intervention: Double papilla flap procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronally repositioned flap procedure
Number of subjects: 20
Study: 7820492

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with glutamine supplementation (20 g/day for 3 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total parenteral nutrition without glutamine supplementation
Number of subjects: 17
Study: 2205135

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.33 mg.kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (placebo) 0.04 ml.kg‐1
Number of subjects: 45
Study: 282538

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic energy therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31243575

Group type: EXPERIMENTAL
Intervention: Clown Intervention (CI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Other Intervention (OI)
Number of subjects: 24
Study: 27762095

Group type: EXPERIMENTAL
Intervention: Test-1 (0.12% CHX and 0.05% CPC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test-2 (0.03% CHX and 0.05% CPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Positive control (0.12% CHX and 0.05% CPC)
Number of subjects: 30
Study: 26485404

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3 g/day for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23410999

Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (FDC) of rifampicin, isoniazid, ethambutol, and pyrazinamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid, ethambutol, and pyrazinamide
Number of subjects: 18
Study: 21422411

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 6055

Group type: COMPARATOR
Intervention: Control (chemotherapy alone)
Number of subjects: 6055

Group type: EXPERIMENTAL
Intervention: Bevacizumab with full-dose anticoagulation
Number of subjects: 6055
Study: 19022863

Group type: EXPERIMENTAL
Intervention: Orthoses wear and stretching (O group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Orthoses wear, stretching, and concentric progressive resistive exercise (OC group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Orthoses wear, stretching, and eccentric progressive resistive exercise (OE group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study: 17302711

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) stimulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Single right ventricular (RV) pacing
Number of subjects: 56
Study: 14764774

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11211134

Group type: EXPERIMENTAL
Intervention: Fetuses of Asian mothers
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fetuses of black mothers
Number of subjects: 170

Group type: COMPARATOR
Intervention: Fetuses of white mothers
Number of subjects: 170

Group type: COMPARATOR
Intervention: Comparison of Asian versus white mothers
Number of subjects: 170

Group type: COMPARATOR
Intervention: Comparison of black versus white mothers
Number of subjects: 170
Study: 11263303

Group type: EXPERIMENTAL
Intervention: Beclomethasone dry powder (BDP, 600 micrograms/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 7946871

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg bolus followed by 30 mg/24 h infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (10% Intralipid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2519671

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bednets (500 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-treated bednets (milk)
Number of subjects: 0
Study: 31112621

Group type: EXPERIMENTAL
Intervention: I-neb (75 mg tobramycin inhalation solution)
Number of subjects: 22

Group type: COMPARATOR
Intervention: PARI-LC Plus (300 mg tobramycin inhalation solution)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both nebulizers (I-neb and PARI-LC Plus)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: I-neb
Number of subjects: 22

Group type: COMPARATOR
Intervention: PARI-LC Plus
Number of subjects: 22